Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

Eunjig Lee, K. R. Kim, Sungkil Lim, H. C. Lee, D. I. Kim, S. H. Kim, K. B. Huh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalEuropean Journal of Endocrinology
Volume131
Issue number1
DOIs
Publication statusPublished - 1994 Jan 1

Fingerprint

Octreotide
Pituitary Neoplasms
Thyrotropin
Somatostatin
Subcutaneous Injections
Thyroid Hormones
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{8bc435b59a7847b28f136facbf8afdf0,
title = "Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)",
abstract = "We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.",
author = "Eunjig Lee and Kim, {K. R.} and Sungkil Lim and Lee, {H. C.} and Kim, {D. I.} and Kim, {S. H.} and Huh, {K. B.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1530/eje.0.1310109",
language = "English",
volume = "131",
pages = "109--112",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). / Lee, Eunjig; Kim, K. R.; Lim, Sungkil; Lee, H. C.; Kim, D. I.; Kim, S. H.; Huh, K. B.

In: European Journal of Endocrinology, Vol. 131, No. 1, 01.01.1994, p. 109-112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

AU - Lee, Eunjig

AU - Kim, K. R.

AU - Lim, Sungkil

AU - Lee, H. C.

AU - Kim, D. I.

AU - Kim, S. H.

AU - Huh, K. B.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

AB - We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

UR - http://www.scopus.com/inward/record.url?scp=0028247380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028247380&partnerID=8YFLogxK

U2 - 10.1530/eje.0.1310109

DO - 10.1530/eje.0.1310109

M3 - Article

VL - 131

SP - 109

EP - 112

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -